Celularity and GX Acquisition Corp. announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity.
Celularity announced the first patient was dosed in a Phase I/II study of human placental hematopoietic stem cell derived NK cells (CYNK-001) for the treatment of adults with COVID-19 as part of a national clinical trial.